This company listing is no longer active
ALBO Stock Overview
Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Albireo Pharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$44.15 |
| 52 Week High | US$45.23 |
| 52 Week Low | US$16.02 |
| Beta | 1.04 |
| 1 Month Change | -1.23% |
| 3 Month Change | 85.66% |
| 1 Year Change | 66.73% |
| 3 Year Change | 98.69% |
| 5 Year Change | 28.53% |
| Change since IPO | 202.40% |
Recent News & Updates
Recent updates
We're Hopeful That Albireo Pharma (NASDAQ:ALBO) Will Use Its Cash Wisely
Jan 02
Rock star Growth Puts Albireo Pharma (NASDAQ:ALBO) In A Position To Use Debt
Oct 25Albireo Pharma achieves positive phase 3 top-line results of Bylvay in Alagille syndrome
Oct 11Albireo Pharma: Assessing The Sagard Deal
Oct 03Albireo gains on royalty agreement for pruritus therapy
Sep 22Albireo gets reimbursed access to liver disease drug Bylvay in Italy
Sep 06These Analysts Just Made A Significant Downgrade To Their Albireo Pharma, Inc. (NASDAQ:ALBO) EPS Forecasts
Aug 23Albireo Pharma GAAP EPS of -$2.04, revenue of $8.2M
Aug 15Albireo: The Commercialization Of Bylvay Is The Key To A Fair Valuation
Jul 22Despite Lacking Profits Albireo Pharma (NASDAQ:ALBO) Seems To Be On Top Of Its Debt
May 10Albireo: A Speculative Play With Upside
May 03Is Albireo Pharma (NASDAQ:ALBO) Using Debt Sensibly?
Feb 02Albireo: Successful And Accelerating Global Launch Drives Sales Revenue
Jan 31Albireo: Reasons For A Successful Transformation Into A Commercial Company
Nov 24Albireo Pharma: A Post Approval Assessment
Aug 09Albireo reports expanded data on Bylvay and A3907 at EASL international liver congress
Jun 21Some Shareholders May find It Hard To Increase Albireo Pharma, Inc.'s (NASDAQ:ALBO) CEO Compensation This Year
Jun 11Why Albireo Must Be Valued Higher Than Its Competitor Based On The Value Of Odevixibat
Apr 26Industry Analysts Just Made A Substantial Upgrade To Their Albireo Pharma, Inc. (NASDAQ:ALBO) Revenue Forecasts
Feb 27Albireo launches late-stage trial of odevixibat in Alagille Syndrome
Dec 17Albireo submits U.S. and European applications for odevixibat in liver disease
Dec 09Albireo Pharma (ALBO) Investor Presentation - Slideshow
Nov 17Albireo Pharma's odevixibat shows durable response in a rare pediatric liver disease
Nov 13Shareholder Returns
| ALBO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 1.2% | -0.4% | -0.6% |
| 1Y | 66.7% | 5.5% | 22.2% |
Return vs Industry: ALBO exceeded the US Biotechs industry which returned 6.8% over the past year.
Return vs Market: ALBO exceeded the US Market which returned -9.2% over the past year.
Price Volatility
| ALBO volatility | |
|---|---|
| ALBO Average Weekly Movement | 27.3% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: ALBO's share price has been volatile over the past 3 months.
Volatility Over Time: ALBO's weekly volatility has increased from 17% to 27% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 130 | Ron Cooper | www.albireopharma.com |
Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases. It also engages in the developing of A3907, which is in Phase I clinical trial for the treatment of adult liver diseases; and A2342, a preclinical candidate to treat adult viral and liver diseases.
Albireo Pharma, Inc. Fundamentals Summary
| ALBO fundamental statistics | |
|---|---|
| Market cap | US$921.13m |
| Earnings (TTM) | -US$131.14m |
| Revenue (TTM) | US$57.39m |
16.1x
P/S Ratio-7.0x
P/E RatioIs ALBO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALBO income statement (TTM) | |
|---|---|
| Revenue | US$57.39m |
| Cost of Revenue | US$2.55m |
| Gross Profit | US$54.84m |
| Other Expenses | US$185.99m |
| Earnings | -US$131.14m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -6.29 |
| Gross Margin | 95.56% |
| Net Profit Margin | -228.51% |
| Debt/Equity Ratio | 0% |
How did ALBO perform over the long term?
See historical performance and comparison